Try our beta test site
1 study found for:    Open Studies | Anaplastic Large Cell | Phase 3
Show Display Options
Rank Status Study
1 Recruiting ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Interventions: Drug: Brigatinib;   Drug: Xalkori (crizotinib)

Study has passed its completion date and status has not been verified in more than two years.